Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
$36.18
-$0.23(-1.55%)
At close: 4:00 PM EST
$36.18
-$0.23(-1.55%)
Day’s Range― - ―
52-Week Range$12.21 - $36.70
Previous CloseN/A
Volume154.73K
Average Volume (3M)600.63K
Market Cap
$1.01B
Enterprise Value$720.33M
Total Cash (Recent Filing)$265.71M
Total Debt (Recent Filing)$346.46M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 11, 2025EPS Estimate
-1.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding27,996,964
10 Day Avg. Volume327,854
30 Day Avg. Volume600,627
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue5.85
Enterprise Value/Gross Profit5.91
Enterprise Value/Ebitda-10.82
Forecast
1Y Price Target
$62.86Price Target Upside73.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Positive Drug Development UpdatesThe study hit the DAS28-CRP primary endpoint for all doses vs. placebo, and rosnilimab demonstrated benefits on other key measures such as ACR20/50/70 scores which were largely durable out to week 38.
Strategic Corporate MovesANAB announced recently that it intends to separate into a biopharma business and a royalty business, which is seen as a strategic move.
Undervaluation And Financial PositionANAB is considered undervalued given shares continue to trade below the modeled value of the Jemperli royalty stream in addition to the company's cash balance.
Bears Say
Drug Efficacy ConcernsThe drug lowered CD122+ CD8+ T cells by ~70%, though overall CD8+ T cell impact was ~20% lower.
AnaptysBio News
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $12.21 and its highest was $36.70 in the past 12 months.
What is AnaptysBio Inc’s market cap?
AnaptysBio Inc’s market cap is $1.01B.
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Nov 11, 2025 which is in 13 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Aug 06, 2025. The company reported -$1.34 earnings per share for the quarter, beating the consensus estimate of -$1.551 by $0.211.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -1.4.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 27,996,964 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.34 in its last earnings report, beating expectations of -$1.551. Following the earnings report the stock price went down -9.627%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Currently, no hedge funds are holding shares in ANAB
AnaptysBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.86 (73.74% Upside)
$62.86 (73.74% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 290.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.56%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on the development of novel therapeutic antibodies for the treatment of inflammatory diseases and cancer. The company leverages its proprietary SHM-XEL™ technology platform to create differentiated antibody candidates, primarily targeting immune-mediated diseases. AnaptysBio’s pipeline includes several promising candidates in various stages of clinical trials, aimed at addressing unmet medical needs in its focus areas.
ANAB Stock 12 Month Forecast
Average Price Target
$62.86
▲(73.74% Upside)
Technical Analysis
Meiragtx Holdings
―
Keros Therapeutics
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Terns Pharmaceuticals
―
Ownership Overview
30.30% Insiders
14.90% Mutual Funds
3.00% Other Institutional Investors
42.21% Public Companies and
Individual Investors